1-3 of 3
Sharon Waymer
Close
Sort by
Journal Articles

Updated Results from a Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL) and Richter's Transformation or Ibrutinib for Patients with Ibrutinib-Resistant Clones

Jennifer A. Woyach, MD, Amy S. Ruppert, MAS, Farrukh T. Awan, Jeffrey Jones, MD MPH, Leslie A. Andritsos, MD, Sharon Waymer, Gerard Lozanski, MD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD
Journal: Blood
Blood (2016) 128 (22): 4386.
https://doi.org/10.1182/blood.V128.22.4386.4386
Published: 2016
Journal Articles

A Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL)

Jennifer A. Woyach, MD, Amy S. Ruppert, MAS, Farrukh Awan, MD MS, Jeffrey A. Jones, MD MPH, Sharon Waymer, Gerard Lozanski, MD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD
Journal: Blood
Blood (2015) 126 (23): 2953.
https://doi.org/10.1182/blood.V126.23.2953.2953
Published: 2015
Journal Articles

FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia

Clinical Trials & Observations
Thomas S. Lin, Ian W. Flinn, Rama Modali, Teresa A. Lehman, Jennifer Webb, Sharon Waymer, Mollie E. Moran, Margaret S. Lucas, Sherif S. Farag, John C. Byrd
Journal: Blood
Blood (2005) 105 (1): 289–291.
https://doi.org/10.1182/blood-2004-02-0651
Published: 2005